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Point: Intensive Glycemic Control and
Mortality in ACCORD—A Chance Finding?
T
heActiontoControlCardiovascular
Risk in Diabetes (ACCORD) study
was designed to assess whether in-
tensive glucose management aimed at a
normalA1C(6%)versusstandardther-
apy aimed at an A1C of 7–8% would re-
duce the risk of cardiovascular disease as
reﬂected by the incidence of a major ad-
verse cardiac event (MACE) such as car-
diovascular death, nonfatal myocardial
infarction, or nonfatal stroke (1). The
study enrolled 10,251 patients, and a
planned mean follow-up of 5.6 years was
expected to provide 89% power to detect
a 15% reduction in MACE risk with in-
tensive versus conventional therapy. Pa-
tients received any one of six anti-
hyperglycemic agents or a variety of
insulins alone or in combination. Eligible
subjects were also randomized to inten-
sive versus conventional lipid and/or
blood pressure control. However, after a
mean of 3.6 years of follow-up, when
62.5% of the planned information had
been accrued, the study was terminated
by the Data and Safety Monitoring
Board (DSMB) in the presence of an in-
creased incidence of mortality with inten-
sive therapy: 257 versus 203 deaths with
standard therapy, corresponding to an
adjusted hazard ratio (HR) of 1.22 (95%
CI [1.01–1.46], P  0.04). The database
used to generate the ﬁnal report to the
DSMB was frozen and then used as the
basis for analyses that were subsequently
published (2).
The initial report (2) stated that “dif-
ferences in the use of drugs (including
rosiglitazone), weight change, and other
factors did not identify an explanation for
the mortality ﬁnding.” Since then the au-
thors have searched in earnest for a bio-
logicalmechanismthatwouldaccountfor
this increase in mortality. None has been
found. Herein I present a synopsis of
these ﬁndings and then suggest another
possible mechanism—that the observed
excessmortalitycouldhavebeenachance
ﬁnding.
Baseline factors
Subgroup analyses within strata deﬁned
by baseline factors can assess whether the
baselinefactormodiﬁestheeffectoftreat-
mentasreﬂectedbyatestofhomogeneity
of treatment effects over strata or a test of
group by covariate interaction. As
pointed out by Wang et al. (3), such as-
sessments should adjust for the number
of subgroup factors since whenever a
sampleissplitintwo,bychancethetreat-
ment group difference in one stratum will
begreaterthanthatinanother.Suchanal-
yses in ACCORD (4) demonstrated nom-
inallysigniﬁcantheterogeneityfor3ofthe
38 factors examined. The Intensive:
Standard (I:S) HR was 1.95 among those
with a history of diabetic neuropathy by
self-report compared with HR  0 for
those without, nominal P  0.0008 be-
tween strata, and P  0.031 when ad-
justed for 38 tests. This suggests that
thosewithpreexistingneuropathymaybe
a vulnerable subset but alone it does not
identify a mechanism for the increased
risk of mortality with intensive therapy.
TheI:SHRwasgreateramongthoseusing
aspirin versus those not using aspirin
(1.45vs.0.95,P0.031)andwasgreater
among those with a baseline A1C 8.5%
versus those with a baseline A1C 8.5%
(1.6 vs. 0, P  0.044). Neither remains
close to being signiﬁcant when adjusted
for 38 such analyses.
Hypoglycemia
Intensive therapy increased the risk of se-
vere hypoglycemia requiring assistance
(HA) and requiring medical assistance
(HMA) approximately threefold versus
standard therapy (5). Contrary to expec-
tation, the risk of hypoglycemia in both
treatment groups increased as the A1C
level increased. Further, within both
treatment groups, those with at least one
episode of HA had a greater risk of mor-
tality than those with no HA, HR  1.79
inintensive,2.93instandard,bothhighly
signiﬁcant.
In additional epidemiological analy-
ses(6),amongthe9,122subjectswhodid
not experience any hypoglycemia, there
was a nonsigniﬁcant increased risk of
mortality with intensive versus standard
therapy, the I:S HR  1.21 (0.99–1.48).
Among the 1,072 who experienced HA,
the I:S HR decreased as the number of
such episodes increased, HR  0.84 after
oneepisode,0.71aftertwo,and0.44after
three. The test of homogeneity, however,
was not statistically signiﬁcant (P 
0.23). A similar pattern was observed for
HMA for which the test of homogeneity
was nominally signiﬁcant at P  0.05.
Glycemia (A1C)
Since intensive therapy was designed to
lower glucose, as measured by A1C, an
association with A1C was carefully ex-
plored in further epidemiological analy-
ses (7). Summary measures of glycemia
were employed as time-dependent co-
variates in regression models, as in like
analyses of the Diabetes Control and
Complications Trial (DCCT) (8) and the
UK Prospective Diabetes Study (UKPDS)
(9).
The decrease in A1C over the ﬁrst 4
months and the decrease over the ﬁrst
year (1-year decrease) had no association
with mortality risk (HR  1.0 and 1.02
per A1C unit decrease, respectively). The
authors also presented a spline-smoothed
estimateofthemortalityriskasafunction
of the 1-year A1C decrease that was ﬂat
over the range of values in both groups,
except that there was the suggestion of an
increased risk among intensive therapy
subjects who were unable to reduce their
A1C levels. However, the regression
model estimated an HR  0.86 per unit
(1%)A1Cdecreaseovertheﬁrstyearwith
intensive therapy versus 0.83 per unit de-
crease in the standard group. Thus, there
is no suggestion that a greater decrease in
A1C over the ﬁrst year is associated with
an increased risk.
The updated mean A1C (average
A1C)atthetimeofeachdeath(ortheend
of follow-up) was signiﬁcantly associated
with mortality in the combined cohort
with a 20% increase in risk of mortality
per unit increase in A1C (HR  1.2, P 
0.0002), whereas the most recent (last)
value had no association (HR  1.06). A
spline-smoothed estimate of the log(HR)
perunitincreaseintheaverageA1Cvalue
in the standard group was essentially ﬂat
(no association) resulting in a model-
estimated HR of 0.98 per unit increase in
A1C. Conversely, in the intensive group,
the log(HR) increased as a linear function
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i.e., a positive rather than a negative asso-
ciation,resultinginanHRof1.66perunit
A1Cincrease(P0.0001),thedifference
in the risk gradients between groups also
being statistically signiﬁcant (P 
0.0007).
Whether a given covariate represents
themechanismbywhichtreatmenthasan
effect on an outcome can be assessed by
the relative magnitude of the treatment
effect in regression models without and
with adjustment for the covariate, say Tu
and Ta, respectively. The metric could ei-
ther be the regression coefﬁcient or the
test statistic value. The percentage of the
treatment effect explained is then quanti-
ﬁed by the percentage reduction in the
treatment effect, i.e., 100  (Tu  Ta)/Tu.
An example was provided by the DCCT
(10). However, if the treatment effect is
unchanged or increases, then the covari-
ate is not related to the mechanism of the
treatment effect. After adjustment for the
average A1C over time, the I:S HR  1.82
increased markedly from the unadjusted
HR of 1.22 in Gerstein and colleagues (2)
and 1.25 in Riddle et al. (7), adjusted for
other factors. This suggests that statisti-
callytheestimatedexcessriskofmortality
with intensive versus standard therapy
wouldbegreateriftheintensiveandstan-
dardtherapygroupshadthesameaverage
A1C over time. Clearly the mean A1C is
not related to the mechanism that led to
the increased incidence of mortality.
Chance
Under Occam’s razor or the principle of
parsimony, chance is the simplest hy-
pothesis that is consistent with the failure
thusfartoidentifyaplausiblemechanism
for the increased risk of mortality with
intensive therapy. A chance ﬁnding or a
false positive type I error is random noise
that is neither predictable nor correlated
with other variables such that it would be
expected that no mechanism could be
identiﬁed. Statistically, the ﬁnding of in-
creased risk of mortality (HR  1.22, P 
0.04) was the third most signiﬁcant of 5
secondary outcomes assessed in Gerstein
andcolleagues(2),therebeinga24%risk
reduction of nonfatal myocardial infarc-
tion (P  0.004) and a 35% risk increase
of cardiovascular death (P  0.02) with
intensive versus standard therapy. Thus,
anadjustedPvalueformortalitywouldbe
0.04  3  0.12. Further, the DSMB met
approximately every 6 months over a
6-year period. Using standard calcula-
tions for repeated signiﬁcance tests (11)
with 10 equally spaced looks and 62.5%
information at the 10th look, the proba-
bility that a single outcome would have
P  0.04 at one of these looks is 0.16.
Thus, the total type I error probability as-
sociated with the mortality difference
could be as high as 0.48.
Further, Figure A2 in the online ap-
pendix for Riddle et al. (7) shows that the
risk of mortality with intensive therapy
was negligibly different between groups
at years 1 and 2, substantially higher with
intensive therapy in year 3, lower than
that with standard therapy in years 4 and
5,andthengreateragainatyear6withno
difference at year 7. There is no systemat-
ically increased risk over time, consistent
with chance as the mechanism.
However, this does not mean that the
investigatorsdonotneedtosearchfurther
for a mechanism. If indeed a mechanism
can be identiﬁed, it could certainly save
lives. The possibilities are limitless, and
some,likethehypothesisofa“toxicsoup”
of multiple agents, may be difﬁcult to as-
sess; but the effort should continue.
DSMB
While the type I (false positive) error
probability is a principal concern when
considering early termination for effec-
tiveness, and the type II (false negative)
error probability for futility, no statistical
boundary or stopping rule is generally
employed for safety. The latter relies on
the judgment of the DSMB as a whole
basedonthetotalityofevidenceavailable.
An excess of 54 deaths with intensive
therapy, even though perhaps not statis-
tically compelling, would cause grave
concern.Thus,conjecturethatthisexcess
could have occurred by chance is not in-
tended, nor should it be in any way con-
strued, to imply that the DSMB acted
unwisely when it terminated the trial.
Their sole responsibility was to weigh the
evidence for potential harm so as to pro-
tect the safety of the subjects enrolled in
the trial. It was not to prove that intensive
therapy was harmful.
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